ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 218 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2021. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,719,245 | -62.0% | 194,705 | -67.1% | 0.01% | -61.5% |
| Q4 2022 | $4,528,129 | +31.9% | 592,687 | +22.9% | 0.03% | +36.8% |
| Q3 2022 | $3,434,000 | +33.8% | 482,309 | +52.0% | 0.02% | +18.8% |
| Q2 2022 | $2,567,000 | -40.3% | 317,327 | +2.4% | 0.02% | -55.6% |
| Q1 2022 | $4,301,000 | +72.9% | 309,850 | +249.7% | 0.04% | +50.0% |
| Q4 2021 | $2,487,000 | +72.0% | 88,615 | +108.3% | 0.02% | +33.3% |
| Q3 2021 | $1,446,000 | +43.2% | 42,533 | +72.1% | 0.02% | +63.6% |
| Q2 2021 | $1,010,000 | -70.0% | 24,710 | -70.5% | 0.01% | -74.4% |
| Q1 2021 | $3,372,000 | +863.4% | 83,764 | +1314.9% | 0.04% | +760.0% |
| Q4 2020 | $350,000 | +118.8% | 5,920 | +80.3% | 0.01% | +150.0% |
| Q3 2020 | $160,000 | +3.2% | 3,283 | +2.6% | 0.00% | -33.3% |
| Q2 2020 | $155,000 | -76.3% | 3,200 | -86.4% | 0.00% | -83.3% |
| Q1 2020 | $655,000 | – | 23,562 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |